Pliant Therapeutics Inc (NASDAQ: PLRX) — Perfil da empresa, notícias e dados financeiros
Pliant Therapeutics develops therapies for fibrosis, focusing on innovative research across multiple organ systems.
Pliant Therapeutics Inc
Pliant Therapeutics (NASDAQ:PLRX) is deeply engaged in the discovery and development of therapies aimed at treating fibrosis, a complex disease process that impacts various tissues and organs throughout the body by progressively scarring them. With a sharp focus on utilizing their expertise in tissue-specific and mechanistic biology, the company aims to halt or reverse the progression of fibrotic diseases. Their projects span across multiple organ systems, including the lungs, liver, and kidneys, reflecting a broad yet focused approach to tackling these challenging conditions. Pliant's objective is to leverage their innovative research to revolutionize the treatment landscape for patients suffering from debilitating fibrotic conditions, providing new hope for effective treatments where options are currently limited.
Resumo
Operações
Produtos e/ou serviços de Pliant Therapeutics Inc
- Bexotegrast (PLN-74809), a small molecule dual selective inhibitor for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
- PLN-1474, a small molecule selective inhibitor intended for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
- A pipeline of small molecule treatments for various fibrotic diseases, utilizing proprietary platform to inhibit integrin functionality and fibrosis progression.
- Research collaboration with Novartis focused on the discovery, development, and commercialization of integrin-targeted therapies for fibrotic diseases.
- Development of integrin-based treatments for muscular dystrophies, aiming to address unmet needs in this area of chronic illness.
equipe executiva do Pliant Therapeutics Inc
- Bernard Jozef CouliePresident, CEO & Director
- Keith Lamont CummingsChief Financial Officer
- Minnie KuoChief Operating Officer
- Rik DerynckScientific Founder & Member of Scientific Advisory Board
- Dean SheppardScientific Founder & Member of Scientific Advisory Board
- Bill DeGradoScientific Founder
- Hal ChapmanScientific Founder & Member of Scientific Advisory Board
- Delphine ImbertChief Technical Officer
- Christopher S. KeenanVice President of Investor Relations & Corporate Communications
- Lily CheungChief Human Resources Officer
Principais indicadores financeiros
Resultados divulgados pela Pliant Therapeutics Inc, em USD.
- Cap. de mercado
- 55,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -150,1 mi | -149,3 mi | |
| 0 | -228,4 mi | -210,3 mi | |
| 1,6 mi | -184,1 mi | -161,3 mi | |
| 9,7 mi | -127,2 mi | -123,3 mi |